Glostrup, Denmark

Jo Slashedrgen Scheel-Kruger

This inventor holds 3 USPTO granted patents. Top assignee: Neurosearch A/s. Active years: 1998-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jo Slashedrgen Scheel-Kruger. Retrieved from https://idiyas.com/inventor/jo-slashedrgen-scheel-kruger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1998-2000

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jo Slashedrgen Scheel-Kruger: Innovator in Neuropharmacology

Introduction

Jo Slashedrgen Scheel-Kruger is a notable inventor based in Glostrup, Denmark. He has made significant contributions to the field of neuropharmacology, particularly through his innovative patents. With a total of three patents to his name, Scheel-Kruger has focused on developing compounds that have the potential to impact neurotransmitter systems.

Latest Patents

His latest patents include "8-azabicyclo[3.2.1.]oct-2-ene derivatives, their preparation and use" and "Fused tropane-derivatives as neurotransmitter reuptake inhibitors." These inventions highlight his commitment to advancing the understanding and treatment of neurological conditions.

Career Highlights

Scheel-Kruger is currently associated with Neurosearch A/S, a company dedicated to innovative research in neuropharmacology. His work at Neurosearch A/S has positioned him as a key player in the development of new therapeutic agents.

Collaborations

Throughout his career, Scheel-Kruger has collaborated with esteemed colleagues such as Peter Moldt and Gunnar M. Olsen. These partnerships have further enriched his research and contributed to the success of his projects.

Conclusion

Jo Slashedrgen Scheel-Kruger exemplifies the spirit of innovation in the field of neuropharmacology. His patents and collaborations reflect his dedication to advancing medical science and improving therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…